Eloralintide vs. retatrutide
Both belong in the metabolic peptide research conversation. Their receptor mechanisms differ, and shared research goals do not make their trial results interchangeable.
| Question | Eloralintide | Retatrutide |
|---|---|---|
| What is it? | A modified amylin analogue, code LY3841136 (Original record). | An investigational single-molecule triple receptor agonist (Original record). |
| Which receptors? | Amylin receptors, with preferential human AMY1 activity in the reported assays (Original record). | GIP, GLP-1 and glucagon receptors (Original record). |
| Development status | Investigational; ENLIGHTEN-1 is a Phase III study (Original record). | Investigational; Lilly's current overview describes Phase 3 development and no regulatory approval (Original record). |
| Can the cited monotherapy trial rank them? | No. The 2025 eloralintide trial compared eloralintide with placebo, not retatrutide; it does not support a head-to-head efficacy or safety ranking (Original record). | |
| Is EloraTZP another name for RETA? | No. EloraTZP is eloralintide plus tirzepatide, a separate investigational combination; retatrutide is a different molecule (Original record; Original record). | |
Compare the question, not just the headline
Keep the trial population, intervention, comparator, time point and analysis approach attached to every result. The sample dossier shows why monotherapy results, a recruiting listing and a combination announcement need separate records.
Educational reference only. No dosing, sourcing, interchangeability or treatment recommendation is provided; no independent expert review is recorded.